Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis

Basit Öğe Kaydı
dc.contributor.authorKöse, Duygu
dc.contributor.authorKöse, Ahmet
dc.contributor.authorHalıcı, Zekai
dc.contributor.authorGürbüz, Muhammet Ali
dc.contributor.authorMaman, Adem
dc.contributor.authorYayla, Muhammed
dc.date.accessioned2022-09-29T08:25:00Z
dc.date.available2022-09-29T08:25:00Z
dc.date.issued2021
dc.departmentALKÜ
dc.description.abstractAim: Melatonin promoted osteoblast differentiation and causes an increase in levels of markers of bone differentiation and proliferation. Ramelteon (RAMEL) activates melatonin receptors and binds to these receptors as non-selective. In this study, we investigated the preventive effects of the melatonin agonist RAMEL on osteoporosis by radiological, histological, and molecularly. Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP), Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animals underwent bilateral ovariectomy. RAMEL was administered orally once a day in the prophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy. Results: Fourteen weeks after ovariectomy, there was a significant reduction in femoral bone mineral density (BMD) (g/cm2) in the OP group compared to the control group. Compared to the OP group, RAMEL treatment significantly increased the BMD level (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2 (RUNX2) mRNA levels were significantly lower in the OP group than in the control group (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in the RAMEL treatment groups than in the OP group (p<0.05). Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, a peripheral melatonin agonist, can be used to prevent osteoporosis.
dc.identifier.doi10.30565/medalanya.939161
dc.identifier.endpage170en_US
dc.identifier.issue2en_US
dc.identifier.startpage164en_US
dc.identifier.urihttps://dergipark.org.tr/tr/download/article-file/1775561
dc.identifier.urihttps://hdl.handle.net/20.500.12868/1713
dc.identifier.volume5en_US
dc.language.isoen
dc.relation.ispartofActa Medica Alanya
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Başka Kurum Yazarı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRamelteon, melatonin, osteoporosis, bone
dc.subjectRamelteon
dc.subjectMelatonin
dc.subjectOsteoporosis
dc.subjectBone
dc.titleRamelteon used to treat insomnia can reduce the occurrence of osteoporosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10.30565-medalanya.939161-1775561.pdf
Boyut:
1.4 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

2021 - Cilt 5 - Sayı 2